Linked Life Data

12669474

Source:http://linkedlifedata.com/resource/pubmed/id/12669474

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-4-2
pubmed:abstractText
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
70-5
pubmed:dateRevised
2011-7-29
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
pubmed:affiliation
Department of Biology, Wheaton College, Wheaton, IL 60187, USA. Roger.H.Kennett@wheaton.edu
pubmed:publicationType
Journal Article, Evaluation Studies